drug

Eltoprazine

MeSH C063828
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Amarantus BioScience Holdings, Inc.
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
NCT01266174Phase 2Completed

KOLs & investigators

1
John G Csernansky, MDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Amarantus BioScience Holdings, Inc.
company
trial
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
PHASE2
trial
indication
Schizophrenia
indication
Cognitive Impairment
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
KOL
John G Csernansky, MD
KOL score 5
person